Minimal transmission in an influenza A (H3N2) human challenge-transmission model within a controlled exposure environment.
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
28
02
2020
accepted:
14
06
2020
revised:
29
07
2020
pubmed:
14
7
2020
medline:
25
8
2020
entrez:
14
7
2020
Statut:
epublish
Résumé
Uncertainty about the importance of influenza transmission by airborne droplet nuclei generates controversy for infection control. Human challenge-transmission studies have been supported as the most promising approach to fill this knowledge gap. Healthy, seronegative volunteer 'Donors' (n = 52) were randomly selected for intranasal challenge with influenza A/Wisconsin/67/2005 (H3N2). 'Recipients' randomized to Intervention (IR, n = 40) or Control (CR, n = 35) groups were exposed to Donors for four days. IRs wore face shields and hand sanitized frequently to limit large droplet and contact transmission. One transmitted infection was confirmed by serology in a CR, yielding a secondary attack rate of 2.9% among CR, 0% in IR (p = 0.47 for group difference), and 1.3% overall, significantly less than 16% (p<0.001) expected based on a proof-of-concept study secondary attack rate and considering that there were twice as many Donors and days of exposure. The main difference between these studies was mechanical building ventilation in the follow-on study, suggesting a possible role for aerosols.
Identifiants
pubmed: 32658939
doi: 10.1371/journal.ppat.1008704
pii: PPATHOGENS-D-20-00335
pmc: PMC7390452
doi:
Substances chimiques
Aerosols
0
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1008704Subventions
Organisme : NCIRD CDC HHS
ID : U01 IP000497
Pays : United States
Déclaration de conflit d'intérêts
I have read the journal's policy and the authors of this manuscript have the following competing interests: JSN-V-T and BK declare previous consultancy fees from H-Vivo plc, unrelated to the current work. JSN-V-T is currently seconded to the Department of Health and Social Care (DHSC), England; the views expressed in this paper are not necessarily those of DHSC. RLW, AG and AM are employees of H-Vivo plc each of whom hold shares and /or share options in the company.
Références
J Infect Dis. 2018 Jul 24;218(5):739-747
pubmed: 29878137
J R Soc Interface. 2009 Dec 6;6 Suppl 6:S783-90
pubmed: 19773292
Proc Soc Exp Biol Med. 1966 Jul;122(3):800-4
pubmed: 5918954
Aerosol Sci Technol. 2013 Jan 1;47(4):444-451
pubmed: 23418400
mBio. 2018 Jan 23;9(1):
pubmed: 29362240
Am Rev Respir Dis. 1963 Sep;88:SUPPL 394-403
pubmed: 14064954
PLoS One. 2012;7(10):e46789
pubmed: 23056454
Nat Commun. 2013;4:1935
pubmed: 23736803
J Immunol. 1946 Feb;52:145-65
pubmed: 21018818
Front Cell Infect Microbiol. 2012 Nov 29;2:150
pubmed: 23226686
Influenza Other Respir Viruses. 2013 Sep;7 Suppl 2:42-51
pubmed: 24034483
PLoS Pathog. 2007 Oct 19;3(10):1470-6
pubmed: 17953482
J Virol. 2016 Nov 28;90(24):11247-11258
pubmed: 27707932
Emerg Infect Dis. 2006 Nov;12(11):1657-62
pubmed: 17283614
Lancet Infect Dis. 2007 Apr;7(4):257-65
pubmed: 17376383
J Infect Dis. 2013 Apr;207(7):1037-46
pubmed: 23372182
Lancet Infect Dis. 2012 Oct;12(10):744; author reply 744-5
pubmed: 23017359
PLoS Pathog. 2013 Mar;9(3):e1003205
pubmed: 23505369
J Hosp Infect. 2013 May;84(1):22-6
pubmed: 23498357
Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):1081-1086
pubmed: 29348203
Am J Epidemiol. 2008 Apr 1;167(7):775-85
pubmed: 18230677
J Infect Dis. 2012 Jan 1;205(1):35-43
pubmed: 22131338
Sci Transl Med. 2013 Sep 18;5(203):203ra126
pubmed: 24048524
Lancet Infect Dis. 2011 Nov;11(11):879-86
pubmed: 21798808
Cell Host Microbe. 2009 Sep 17;6(3):207-17
pubmed: 19664979
Lancet Respir Med. 2014 Jun;2(6):445-54
pubmed: 24717637